SEC Form 4 · accession 0000899243-18-030964
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anastasios Gianakakos
Officer — President and CEO · Director
Period of report
Dec 12, 2018
Accepted (ET)
Dec 13, 2018 · 8:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 12, 2018 | S | 3,000 | $55.6817 | D | 72,087 | D | |
| Common Stock | holding | — | — | — | 85,973 | I | By Reporting Person's Trust 2 | |
| Common Stock | holding | — | — | — | 500,000 | I | By Reporting Person's Trust 3 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 1 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 2 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 3 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person
- F2Represents the weighted average sale price of the shares sold ranging from $55.33 to $55.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price